Today is the last day of #SfN2023 and the final call to view the latest data on how our ioCells™ are empowering CNS drug discovery! Learn how our ioDisease Model Cells™ for Huntington's disease and amyotrophic lateral sclerosis (ALS) are being used to model neurodegeneration in vitro, to support CNS drug discovery programs at Charles River Laboratories. Poster 467.12 | Establishing a hPSC-derived Huntington’s disease neuronal model suitable for phenotypic drug screening and to identify small molecule modulators of mutant HTT Session: Huntington’s Disease: Molecular and Cellular Mechanisms Time: 11 am - 12 pm Larissa Butler et al, Charles River Laboratories Poster 533.19 | TDP-43 dysfunction and STMN-2 mis-splicing upon proteasomal inhibition in iPSC derived neuronal ALS model Session: ALS: Patient Research and Human-derived Cellular Models Time: 4 - 5 pm Dario Magnani et al, Charles River Laboratories We are also excited to showcase our newest products in the market ioMotor Neurons™ and ioSensory Neurons™! Join the poster sessions to discover the functional data presented by our scientific experts! Poster 489.02 | Rapid and consistent generation of functional motor neurons from reprogrammed human iPSCs using opti-ox technology Session: Motor Neurons: Development, Identification, Intrinsic Properties and Modulation Time : 9 - 10 am Marcos Herrera Vaquero et al, bit․bio Poster 544.05 | Optimised and scalable reprogramming of human iPSCs to generate nociceptor sensory neurons for the study of pain mechanisms and neuropathies Session: Behavioural and Physiological Pain Models Time: 1 - 2 pm Tony Oosterveen, bit․bio View the full agenda: https://hubs.ly/Q028_5kr0 Come meet our scientists at booth 2001! #research #DrugDiscovery #optiox #ioCells #iPSC #neuroscience #HTS #neuron #array #data #microglia #neurodegeneration #ALS #HuntingtonsDisease
